- Nurix Therapeutics (NRIX, Financial) to discuss new data from Phase 1 trial of bexobrutideg (NX-5948) in a webcast on June 12, 2025.
- Data includes efficacy in relapsed refractory CLL and safety in Waldenström macroglobulinemia.
- The webcast and conference call will be accessible via Nurix's website, with a replay available for 30 days.
Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, is set to host a webcast conference call on June 12, 2025, at 8:00 a.m. ET to discuss new findings from the Phase 1 clinical trial of bexobrutideg (NX-5948). This data will be showcased at the 30th European Hematology Association Congress in Milan, Italy. The webcast aims to cover the drug's performance in treating relapsed refractory chronic lymphocytic leukemia (CLL) and its clinical activity and safety in patients with Waldenström macroglobulinemia.
Two poster presentations will highlight the efficacy and safety of bexobrutideg. Dr. Talha Munir will present outcomes related to its effects on relapsed refractory CLL, while Dr. Dima El-Sharkawi will focus on its impact on Waldenström macroglobulinemia.
Participants can access the live webcast through the Events page in the Investors section of Nurix's website or by dialing 877-346-6112 in the U.S. and 1-848-280-6350 for international callers. A replay of the webcast will be archived for approximately 30 days post-event, providing extended access to the discussion.
